Abstract: The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.

Abstract: A peptide Scyreprocin of Scylla paramamosain, an amino acid sequence of the peptide Scyreprocin is SEQ ID NO 01.

Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.

Abstract: Disclosed in one aspect is a pickled vegetable-based edible packaging paper, the raw material of which is composed of the following components in parts by weight: 92-95 parts of a high dietary fiber-level pickled vegetable, a compounding thickener (0.6-0.8 parts of pectin, 0.6-0.8 parts of potato starch, and 0.2-0.4 parts of soy protein), and a compounding plasticizer (3-4 parts of sorbitol, and 0.5-1.5 parts of citral); and further disclosed in another aspect is a method for preparing a pickled vegetable-based edible packaging paper. The pickled vegetable paper of the present invention is a novel pickled vegetable-based product having both edible and practical functions, which product is rich in dietary fibers, retains the unique flavor and color of the pickled vegetable, has toughness and non-stickiness to teeth, and is soft and easy to process after being wetted.

Abstract: Provided is an antimicrobial peptide Sparamosin from Scylla paramamosain. The Sparamosin mature peptide and its functional domain Sparamosin26-54 were synthesized by solid-phase synthesis with a purity of over 95%. Both Sparamosin and Sparamosin26-54 exhibit strong antimicrobial activity. More importantly, Sparamosin26-54 has strong antifungal activity and could inhibit the growth of a variety of yeasts and filamentous fungi. Based on the potent antimicrobial activities of Sparamosin and Sparamosin26-54, both peptides could be developed as alternatives for conventional antibiotics, antimicrobial agents, feed additives in aquaculture and livestock, preservatives, and mold inhibitors.

Abstract: The present disclosure discloses an electronic cigarette with a rotatable mouthpiece. The electronic cigarette comprises a battery assembly and an atomizing assembly. The battery assembly comprises a battery and a casing. The atomizing assembly comprises a mouthpiece, an outer sleeve, and a cartridge. The outer sleeve is hinged to casing through a cardinal axis. The cardinal axis is accommodated in a guide rail groove, and is slidable along the guide rail groove. The sliding direction of the cardinal axis is the same as the axial direction of the casing. After using the electronic cigarette, the mouthpiece could be rotated and stored in the casing conveniently, and keep cleaning.

Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.

Abstract: The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.

Abstract: Provided is an antimicrobial peptide Sparamosin from Scylla paramamosain. The Sparamosin mature peptide and its functional domain Sparamosin26-54 were synthesized by solid-phase synthesis with a purity of over 95%. Both Sparamosin and Sparamosin26-54 exhibit strong antimicrobial activity. More importantly, Sparamosin26-54 has strong antifungal activity and could inhibit the growth of a variety of yeasts and filamentous fungi. Based on the potent antimicrobial activities of Sparamosin and Sparamosin26-54, both peptides could be developed as alternatives for conventional antibiotics, antimicrobial agents, feed additives in aquaculture and livestock, preservatives, and mold inhibitors.

Abstract: Disclosed in one aspect is a pickled vegetable-based edible packaging paper, the raw material of which is composed of the following components in parts by weight: 92-95 parts of a high dietary fiber-level pickled vegetable, a compounding thickener (0.6-0.8 parts of pectin, 0.6-0.8 parts of potato starch, and 0.2-0.4 parts of soy protein), and a compounding plasticizer (3-4 parts of sorbitol, and 0.5-1.5 parts of citral); and further disclosed in another aspect is a method for preparing a pickled vegetable-based edible packaging paper. The pickled vegetable paper of the present invention is a novel pickled vegetable-based product having both edible and practical functions, which product is rich in dietary fibers, retains the unique flavor and color of the pickled vegetable, has toughness and non-stickiness to teeth, and is soft and easy to process after being wetted.

Abstract: The present disclosure provides an electronic cigarette having an invertible mouthpiece. The electronic cigarette includes a battery assembly and an atomization assembly, the battery assembly including a battery and a housing, and the atomization assembly including a mouthpiece, an outer sleeve and a cartridge. The atomization assembly and the battery assembly are in pluggable connection. The housing defines a groove in the upper part thereof. The outer sleeve has a tail end accommodated into the groove in a working state. The atomization assembly is inverted and the mouthpiece is accommodated into the groove in a receiving state. After the electronic cigarette is used, the mouthpiece can be inverted conveniently and can be completely hidden in the housing to be protected against contamination.

Abstract: The present disclosure discloses an electronic cigarette with a rotatable mouthpiece. The electronic cigarette comprises a battery assembly and an atomizing assembly. The battery assembly comprises a battery and a casing. The atomizing assembly comprises a mouthpiece, an outer sleeve, and a cartridge. The outer sleeve is hinged to casing through a cardinal axis. The cardinal axis is accommodated in a guide rail groove, and is slidable along the guide rail groove. The sliding direction of the cardinal axis is the same as the axial direction of the casing. After using the electronic cigarette, the mouthpiece could be rotated and stored in the casing conveniently, and keep cleaning.

Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.

Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.